Abstract Little is known about the outcomes of extremely low birth weight (ELBW) preterm infants with congenital heart defects (CHDs). The aim of this study was to assess the mortality, morbidity, and early childhood outcomes of ELBW infants with isolated CHD compared with infants with no congenital defects. Participants were 401-1,000 g infants cared for at National Institute of Child Health and Human Development Neonatal Research Network centers between January 1, 1998, and December 31, 2005. Neonatal morbidities and 18-22 months' corrected age outcomes were assessed. Neurodevelopmental impairment (NDI) was defined as moderate to severe cerebral palsy, Bayley II mental or psychomotor developmental index \70, bilateral blindness, or hearing impairment requiring aids. Poisson regression models were used to estimate relative risks for outcomes while adjusting for gestational age, small-forgestational-age status, and other variables. Of 14,457 ELBW infants, 110 (0.8 %) had isolated CHD, and 13,887 (96 %) had no major birth defect. The most common CHD were septal defects, tetralogy of Fallot, pulmonary valve stenosis, and coarctation of the aorta. Infants with CHD experienced increased mortality (48 % compared with 35 % for infants with no birth defect) and poorer growth. Surprisingly, the adjusted risks of other short-term neonatal morbidities associated with prematurity were not significantly different. Fifty-seven (52 %) infants with CHD survived to 18-22 months' corrected age, and 49 (86 %) infants completed follow-up. A higher proportion of 
Introduction
Congenital cardiac anomalies are among the most commonly reported birth defects, with an incidence of 5-8/ 1,000 live births [12] . As many as 1 in 6 infants born with cardiac anomalies are born preterm [24] , yet data are limited on the long-term outcome of these infants, especially extremely low birth weight (ELBW) preterm infants. It is unknown if ELBW infants with major structural cardiac anomalies survive beyond their initial hospitalization and what factors are associated with increased morbidity and mortality. Surgical advances now permit repair or palliation even in this high-risk group; yet concerns regarding quality of life and anticipated long-term outcomes of survivors may influence surgical decision making and treatment options. The aims of this study were to assess mortality, morbidity, and 18-22 months' corrected age neurodevelopmental outcomes in a cohort of infants weighing 401-1,000 g at birth, with and without congenital heart defects (CHDs), treated at the clinical centers of the National Institute of Child Health and Human Development Neonatal Research Network. We hypothesized (1) that preterm ELBW infants with CHD and no cooccurring noncardiac defect or syndrome would have higher morbidity and mortality compared with ELBW infants without congenital defects or syndromes and (2) that infants with more severe lesions would have poorer outcomes.
Methods
Infants weighing 401-1,000 g born between January 1, 1998, and December 31, 2005 , and admitted to a clinical center of the Neonatal Research Network within 14 days of birth were studied. All centers were performing complex neonatal cardiac surgery during the study period. Infants with isolated CHD were compared with infants having no congenital defects. Infants with other major birth defects, including those with chromosomal anomalies sometimes co-occurring with cardiac defects (e.g., trisomy 21, VACTERL association) were excluded. The study was approved by the Institutional Review Committee at each center, and parents provided informed consent for prospective follow-up as required.
Trained research nurses entered maternal, perinatal, and infant data collected from birth to discharge, death, or 120 days into a registry maintained by the Network [22] . Infants hospitalized[120 days were followed-up to 1 year. Neonatal information recorded included birth weight (BW), gestational age (GA), sex, race, mode of delivery, survival, and coded cause of death. Diagnoses during the initial hospital stay were recorded for infants surviving [12 h and included presence of a patent ductus arteriosus (PDA), infections, necrotizing enterocolitis (NEC), intracranial hemorrhage (ICH), periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), and bronchopulmonary dysplasia (BPD). Major birth defects were recorded using codes from a predefined list. Defects not specified in the list were recorded using codes for ''other'' defects in each area (e.g., ''other congenital heart defects'') with specific information entered in text fields. Predefined cause of death included ''congenital malformation'' and ''other'' for which specific information also was provided in a text field.
Growth charts developed by Alexander [2] were used to classify infants as small for GA at birth (SGA), which was defined by a birth weight \10th percentile. NEC was defined as modified Bell's stage IIA or greater [28] . Earlyonset (within 72 h of birth) sepsis (EOS) and late-onset (after 72 h) sepsis (LOS) were defined by a positive blood culture and antibiotic therapy for C5 days. ICH and cystic PVL were defined based on cranial sonogram, with ICH grade from the sonogram showing the most severe hemorrhage. Retinopathy of prematurity was defined by ophthalmologic examination. BPD was defined as chronic lung disease requiring supplemental oxygen at 36 weeks postmenstrual age (PMA). Growth parameters at 36 weeks' PMA included measures of weight, length, and head circumference taken between 35 and 37 weeks' PMA.
Surviving infants were eligible for a comprehensive follow-up visit at 18-22 months' corrected age, which included a caregiver interview, medical and social history, measurement of growth parameters, neurological examination, and developmental evaluation (using the Bayley Scales of Infant Development-II [6] ) administered by certified examiners trained to reliability. CP was defined as a nonprogressive disorder of the central nervous system characterized by abnormal tone in at least one extremity and abnormal control of movement and posture. Scores were reported for the Bayley Mental Developmental Index (MDI) and the Psychomotor Developmental Index (PDI), with a score of \70 ([2 SD below the mean) indicating significantly delayed performance. Infants who were profoundly delayed and untestable were assigned MDI and PDI scores of 49. The child's vision and hearing status were determined by caregiver report and results of testing (when available). Neurodevelopmental impairment (NDI) was defined as one or more of the following: MDI \ 70, PDI \ 70, moderate to severe cerebral palsy, bilateral blindness, or hearing loss requiring amplification.
Statistical Analysis
Statistical significance for unadjusted comparisons between groups was determined by Fisher's exact or chi-square tests for categorical variables and by Student t tests for continuous variables. Kaplan-Meier survival curves were used to estimate median length of hospital stay (time from birth to discharge with deaths treated as censored observations) with statistical significance between groups determined by the log rank test.
Poisson regression models with robust variance estimators [30] were used to compare risk of death, in-hospital morbidities, and neurodevelopmental outcomes at 18-22 months' corrected age between children with CHD and no major birth defect while adjusting for variables known to affect these outcomes. Models used data from the entire cohort and included a birth defect group indicator (CHD, other birth defect, no major birth defect) to allow for pairwise comparisons between infants with CHD and no major birth defects. Adjusted relative risks, (RRs) 95 % confidence intervals (CIs), and Wald chi-square tests are reported based on parameter and variance estimates from these models, and p values were not adjusted for multiple comparisons.
Results

Study Population
Of 14,457 ELBW infants born between January 1, 1998, and December 31, 2005, 110 (0.76 %) were born with isolated CHD; 460 (3.2 %) had other types of major birth defects; and 13,887 (96 %) had no major birth defect. The proportion of infants with CHD ranged from 0.3 to 1.75 % across the 19 study centers (1-16 infants/center). Among those not included in the CHD group were 44 infants with other noncardiac congenital anomalies or syndromes that included a CHD (14 with chromosomal abnormalities, 1 with Goldenhar syndrome, and 29 with multiple defects).
Of the 110 ELBW infants with CHD, the most common defects were ventricular septal defects [VSDs (18 %) ] and tetralogy of Fallot [TOF (14 %)] (Table 1) . Infants with CHD were of later GA, weighed more, and had larger head circumference at birth than infants with no major birth defect ( Table 2) . A greater proportion of infants with CHD were SGA compared with those having no birth defect (27 vs. 15 %, p = 0.001) . Although the proportion of infants with 1 min Apgar score B3 was similar in both groups, the proportion at 5 min was smaller in the CHD group (7 vs. 20 %, p = 0.001 b Includes large aortopulmonary collaterals (n = 1); hypoplastic pulmonary arteries (n = 1); right coronary artery originating from left cusp (n = 1); anomalous left coronary artery (n = 1); hypoplastic aortic arch (n = 1); univentricular heart with common AV valve; total anomalous venous return and pulmonic stenosis (n = 1); and multiple cardiac anomalies [partial anomalous pulmonary venous return to the superior vena cava, left pulmonary stenosis, secundum ASD, and anomalous coronary artery (n = 1)] without a birth defect (adjusted RR 0.60, 95 % CI 0.26-1.35, p = 0.22). Among those who died, median time of death was day 16 for infants with CHD and day 3 for infants with no major birth defect. Cause of death was coded as congenital malformation for 32 (67 %) of the 48 infants with CHD who died during the initial hospitalization, including 9 infants who died within 24 h. Respiratory support was withheld or withdrawn for 8 of these 9 infants. For the remaining infants, death was attributed to sepsis/infection and/or NEC in 7 infants (15 %); respiratory distress syndrome with other complications in 3 infants (6 %); BPD with or without complications in 2 infants (4 %); severe ICH with or without complications in 2 infants (4 %); and ''other'' in 2 (11) infants (4 %). In contrast, among the 4,698 infants with no birth defects who died before discharge, death was most frequently attributed to immaturity (37 %) followed by RDS (25 %), and sepsis and/or NEC (16 %). After neonatal intensive care unit (NICU) discharge and before 18-22 months' corrected age, 5 infants with CHD died (5 % of 110) and 171 of those with no major birth defect died (1 % of 13,887) ( Table 3) . Among the five infants with CHD who died, cause of death was coded as congenital malformation for 1 infant with transposition of the great vessels, as sepsis/infection for 1 infant, ''other'' for 1 infant (specified as ''cardiac''), and ''unknown'' for 2 infants.
The proportion of infants with CHD who survived to 18-22 months' corrected age varied by type of CHD (Table 4 ). All 10 infants with pulmonary valve stenosis (PVS) survived to discharge with 9 infants (90 %) surviving to 18-22 months' corrected age. Both infants with partial anomalous pulmonary venous return survived to 18-22 months' corrected age. The proportion surviving with an atrial or ventricular septal defect was [80 %. In contrast, 5 of 15 infants (33 %) with TOF and 4 of 9 infants (44 %) with coarctation of the aorta (CoA) survived. None of the 9 infants with hypoplastic left heart syndrome (HLHS) nor the 2 infants with hypoplastic right heart syndrome (HRHS) survived to hospital discharge.
Morbidities
Of the 110 ELBW infants with CHD, 105 (95 %) survived [12 h compared with 12,034 (87 %) without major birth defects. A greater proportion of those with CHD had a PDA, which may have been secondary to prostaglandin therapy. No differences were found in the rates of NEC, seizures, late-onset sepsis, severe ICH, PVL, or ROP (Table 5) . Thirty-four infants with CHD died before 36 weeks PMA; 65 remained hospitalized; 1 was discharged; and 5 were transferred. Among the 71 infants with CHD assessed, 58 % had BPD compared with 50 % of infants without birth defects (p = 0.2). Infants with CHD compared with those without CHD weighed less at 36 weeks PMA (1,648 vs. 1,824 g, p = 0.02) and had smaller head circumference (29 vs. 30 
Characteristics and Outcomes of Children Followed-Up
Survivors to 18-22 months' corrected age included 57 of 110 (52 %) infants with CHD and 9,018 of 13,887 (65 %) infants with no major birth defect. Among survivors, 86 % in each group attended the follow-up assessment between September 1999 and December 2008. Of 49 infants with CHD evaluated, the most common heart defects were ventricular and atrial septal defects (VSDs and ASDs, respectively), PVS, and TOF-defects seen most frequently among all infants with CHD (Table 4) . Together, infants with these defects comprised 71 % of infants with CHD seen at follow-up and 51 % of infants with CHD at birth.
CHD survivors were on average of later gestational age, and a higher proportion were SGA at birth compared with infants with no major birth defects who were assessed at follow-up (Table 6 ). Although the proportion of non-Hispanic black infants was similar in the two groups in the birth cohort, among those assessed at follow-up the proportion was higher among those with CHD than among those without birth defects (56 vs. 42 %).
Risk of death before 18-22 months' corrected age or survival with NDI at 18-22 months' corrected age was (3) 576 (4) 4-7 days 7 (6) 359 (3) 8-14 days 4 (4) 420 (3) 15-28 days 9 (8) 500 (4 RACHS-1 Risk Adjustment in Congenital Heart Surgery-1 [14] a Percents are among total number of infants with each type of CHD. Number of survivors to 18-22 months' corrected age includes 1 child with a VSD who had an incomplete follow-up assessment and is not counted among survivors with follow-up and 7 children not seen at the follow-up visit who were presumed alive based on last contact b Includes one infant with complete AV canal and TOF c Includes large aortopulmonary collaterals (n = 1); hypoplastic pulmonary arteries (n = 1); right coronary artery originating from the left cusp (n = 1); anomalous left coronary artery (n = 1); hypoplastic aortic arch (n = 1); univentricular heart with common AV valve, total anomalous venous return, and pulmonic stenosis (n = 1); and multiple cardiac anomalies [partial anomalous pulmonary venous return to the superior vena cava, left pulmonary stenosis, secundum ASD, anomalous coronary artery (n = 1)] survivors with CHD evaluated required hearing aids. Hypotonia was present in 6 % of infants with CHD and in 5 % of those without birth defects. Seven (14 %) children with CHD were rehospitalized four or more times since the initial hospitalization compared with 7 % of those without birth defects (p = 0.2). Survivors with CHD showed poorer growth than those with no major birth defect.
Discussion
Of every 1,000 infants in our ELBW series, 7.6 were diagnosed with CHD. Not surprisingly, these ELBW infants had a higher risk of death or neurodevelopmental impairment compared with infants having no structural anomaly or identifiable syndrome. For certain diagnoses, PDA patent ductus arteriosus, NEC necrotizing enterocolitis, LOS late-onset sepsis, ICH intracranial hemorrhage, PVL periventricular leukomalacia, ROP retinopathy of prematurity, PMA postmenstrual age, BPD bronchopulmonary dysplasia, SD standard deviation, NA not applicable a The following information (no. of infants) was missing: PDA = 10, NEC = 2, seizures = 2, LOS = 7, ICH = 7, PVL = 5, ICH/PVL = 40, ROP = 1, ROP stage 3? = 9, and BPD = 6. The majority of infants with missing information were in the ''no birth defect'' group b RRs, CIs, and p values for categorical outcomes from a modified Poisson regression model fit to each outcome that used data from the entire cohort and included study center, GA (\23, 23-24, 25-28, 29-32 , and C33 weeks), SGA, male sex, and birth defect group (CHD, other birth defect, no birth defect). p values were determined by Wald chi-square tests and indicate whether risk differs between the groups (RR different from 1.0). Adjusted p value for continuous outcomes (weight, length, head circumference at 36 weeks PMA) were calculated by Student t test from a linear regression model that included study center, GA, SGA, male sex, and birth defect group c Severe ICH was defined as grade 3 or 4 d PVL was determined based on a sonogram taken B28 days of birth and/or a sonogram taken [28 days and closest to 36 weeks PMA. Severe ICH/PVL outcome percents were based on infants with nonmissing ICH and PVL outcomes, except that a diagnosis of either condition was sufficient to set the outcome to yes e BPD was defined as supplemental oxygen use at 36 weeks PMA. Eighty-five percent of surviving infants were still in the hospital at 36 weeks PMA. BPD was defined based on oxygen use at discharge or transfer for the remainder unless status at 36 weeks was known f Numbers shown are infants who had at least one 36 week measurement. In this group of infants, information was missing for weight = 12, length = 970, and head circumference = 366 such as Risk Adjustment in Congenital Heart Surgery-1 category 1-2 lesions [14] , both survival and 18-22 months' corrected age outcome were comparable with those of infants without birth defects. In contrast, the few infants with category 4-6 lesions (infants who likely required prostaglandin therapy and early palliative surgery) had 100 % mortality or impairment. Although our series of ELBW infants is small, it provides more detailed follow-up data than any reported to date in this population. The finding that some ELBW infants with CHD survive without added morbidity is encouraging in view of the marked prematurity of this group. Even a low-risk lesion, such as a VSD, may present unique challenges for the management of an extremely preterm infant at risk for bronchopulmonary dysplasia, necrotizing enterocolitis, and intracranial hemorrhage or periventricular leukomalacia. Limited information regarding the outcomes of VLBW and ELBW infants with CHD is available. Published Both private and public 1 (2) 480 (6) Self-pay/uninsured 0 (0) 170 (2) SD standard deviation a The following maternal and neonatal information (no. of infants) was missing: maternal age = 1, antenatal steroids = 24, c-section delivery = 9, gestational age = 2, SGA = 2, race/ethnicity = 6, Apgar at 1 min = 84, Apgar at 5 min = 83, primary caregiver at follow-up = 34, primary caregiver marital status = 56, mother's education at follow-up = 371, primary caregiver's education at follow-up = 101, and child's insurance = 55. The majority of infants with missing information were in the ''no birth defect'' group b p value for a difference between groups was determined by Student t test (for continuous variables), Fisher's exact test, or chi-square test of general association studies focus primarily on select infants offered surgical intervention, with no information on excluded infants and no information on morbidities of concurrent control groups of ELBW infants without CHD. Using a prospectively collected population-based database in Australia, Dimmick et al. [10] reported outcomes after surgery in infants with birth weight B2,500 g. A total of 121 LBW infants underwent cardiac surgeries; most (81 %) underwent palliative procedures in the neonatal period. The 2 year mortality rate was 31 %. Factors associated with mortality included BW \ 1,500 g, low weight at surgery, and low initial Apgar score. By 2 years of age, at least 33 % of survivors were known to have neurodevelopmental delay, and 41 % were lost to follow-up. Kopf and Mello reported surgical outcomes for 32 LBW infants (1,320-2,500 g) in Connecticut treated in a statewide cardiac surgery protocol [15] . Delay in surgery offered no survival benefit and increased costs. Other studies have reported a strong association between low birth weight, weight at time of surgical intervention, and higher morbidity and mortality [9, 16] . Sutton et al. [23] reported on cardiac catheterization in infants weighing \1,500 g in a 3:1 case-control study. Many of their LBW infants were premature and had left-sided obstructive lesions. There were no significant differences in the rates of minor or major complications, blood transfusions, or successful interventions between the LBW and control infants. There was a trend toward higher mortality in the LBW group. No data on longer-term outcomes were reported. Recently, Archer et al. [3] reported the distribution and mortality of VLBW infants with CHD regardless of surgical intervention. They studied 99,786 infants with birth weight of 401-1,500 g who were cared for in the NICUs of the Vermont Oxford Network. Eight hundred ninety-three neonates were found to have serious congenital heart disease (8.9/1,000 compared with 7.6/ 1,000 in our \1,000 g cohort). The most common lesions were TOF, CoA, and atrioventricular (AV) canal defects. Infants with septal defects were excluded. VSDs were the most common structural heart defect in our cohort and are the third most common indication for cardiothoracic surgery in VLBW infants [25] . Otherwise, the distribution of CHD was quite similar and interestingly, the percentage of premature infants with TOF again was greater than that CP cerebral palsy a NDI could not be determined for 626 children who survived and who attended follow-up. The following information (no. of infants) was missing: MDI = 601 infants, PDI = 663, cerebral palsy = 33, blindness = 34, hearing loss = 66, hypotonia = 70, rehospitalizations = 38, weight = 27, length = 44, and head circumference = 35. The majority of infants with missing information were in the ''no birth defect'' group b RR for blindness and p values for blindness and hearing loss were unadjusted due to small sample sizes. For the other outcomes, adjusted RRs, CIs, and p values were from a modified Poisson regression model that used data from the entire cohort. The model fit to the death or NDI composite outcome included study center, gestational age (\23, 23-24, 25-28, 29-32 , and C33 weeks), SGA, male sex, and birth defect group (CHD, other birth defect, no birth defect). Models fit to NDI, MDI, PDI, and CP included these variables as well as severe ICH, PVL, BPD, mother's education at follow-up (Chigh school degree, \high school degree, unknown), and mother's medical insurance at follow-up (public, private, public and private, self-pay/uninsured). Adjusted p values for growth measures were determined by Student t test from a linear regression model that included the covariates listed reported among term infants [11] . Mortality rate before hospital discharge was 44 %, identical to that in our birth cohort and nearly double that reported among older preterm (\37 weeks) or low-weight neonates [1, 8] . No data on timing of deaths or longer-term outcomes were provided. In our study, infants with CHD died later than infants without confirmed birth defects; it is possible that some non-CHD infants may have had undiagnosed anomalies. In addition, infants with CHD had poorer head and somatic growth and longer hospital stays, both of which are associated with poorer neurodevelopmental outcomes. Fiftyseven percent of children with CHD had NDI, and 12 % had moderate to severe CP. Interestingly, 6 % had hypotonia, and only 31 % had significant psychomotor delay (PDI \ 70), both of which are seen more frequently in term CHD patients. In term infants, the neurodevelopmental sequelae are diverse [7, 19] . In a recent cohort study with exclusion criteria similar to ours (i.e., excluding infants with expected developmental sequelae and syndromes), 42 % of infants with CHD exhibited gross and fine motor delays ([1.5 SD below the mean), 25 % exhibited global delays, and 41 % exhibited neurological abnormalities at 21 months' mean follow-up [17] .
Limitations
Long-term follow-up may assist clinicians in planning interventions and support services and selecting treatment strategies that optimize disability-free survival. Despite carefully planned follow-up, our study has a number of limitations. First, our birth cohort is not population based. Second, we have no normal birth weight population for comparison, so we can only speculate on the contribution of preterm morbidities on the neurodevelopmental sequelae of our cohort. Third, congenital heart defects are rare; thus, we had many fewer cases than controls. We elected to analyze all existing Neonatal Research Network (NRN) data while adjusting for all known and available confounders as opposed to performing a matched case-control study. Fourth, we have limited information on the intensive care and surgical management of the ELBW infants in our cohort because these data are not included in the NRN database (e.g., medications used; surgical procedures, including palliative or corrective approach; timing of interventions; and perioperative complications). Curzon et al. [9] presented data on surgical outcomes of LBW infants compared with normal birth-weight infants with CHD using the Society of Thoracic Surgeons Congenital Heart Surgery Database, and they showed that outcomes varied by type of procedure. The RR of mortality ranged from 2.7 to 5.4 for infants weighing 1-2.5 versus 2.5-4 kg at the time of surgical intervention. Surgical outcome data are important to the planning of care for preterm infants.
Preterm infants with CHD pose multiple diagnostic and therapeutic challenges in view of their small size and immaturity. Moreover, in view of the rarity of their condition and the heterogeneity of associated cardiac and noncardiac comorbidities, they present unique ethical and decision-management dilemmas (including deliberate therapeutic abstention in some cases). With the continued advancement of prenatal screening techniques and critical and surgical care management, the opportunity for focused cardiac interventions continues to expand. As these therapeutic techniques evolve (e.g., hybrid approaches [21, 29] , in utero valvuloplasty or atrial septostomy for HLHS or HRHS [4, 5, 13, 18, 20, 26, 27] ), larger numbers of premature neonates with CHD may survive. Beyond survival and short-term management options, comorbidities and long-term neurodevelopmental outcomes must be evaluated. This study sets the stage for detailed assessment of follow-up outcomes for these high-risk neonates.
